4.7 Article

Prevalence of Subclinical Papillary Thyroid Cancer by Age: Meta-analysis of Autopsy Studies

期刊

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 107, 期 10, 页码 2945-2952

出版社

ENDOCRINE SOC
DOI: 10.1210/clinem/dgac468

关键词

thyroid cancer; papillary; prevalence; meta-analysis; autopsy

资金

  1. National Institutes of Health (NIH), National Cancer Institute [1R01CA251566, 3R01CA251566-02S1]
  2. NIH, National Institute on Deafness and Other Communication Disorders [T32DC009401]
  3. Australian National Health and Medical Research Council (NHMRC Investigator Grant) [1174523]

向作者/读者索取更多资源

This meta-analysis explores the prevalence of subclinical papillary thyroid cancer (PTC) throughout a person's lifetime. The study finds that the prevalence of subclinical PTC remains stable across all age groups and there is no higher prevalence in middle age, despite higher observed incidence rates in this age group. These findings provide unique insights into the relationship between subclinical PTC and age.
Context It is not known how underlying subclinical papillary thyroid cancer (PTC) differs by age. This meta-analysis of autopsy studies investigates how subclinical PTC prevalence changes over the lifetime. Methods We searched PubMed, Embase, and Web of Science databases from inception to May 2021 for studies that reported the prevalence of PTC found at autopsy. Two investigators extracted the number of subclinical PTCs detected in selected age groups and extent of examination. A quality assessment tool was used to assess bias. Logistic regression models with random intercepts were used to pool the age-specific subclinical PTC prevalence estimates. Results Of 1773 studies screened, 16 studies with age-specific data met the inclusion criteria (n = 6286 autopsies). The pooled subclinical PTC prevalence was 12.9% (95% CI 7.8-16.8) in whole gland and 4.6% (2.5- 6.6) in partial gland examination. Age-specific prevalence estimates were <= 40 years, 11.5% (6.8-16.1); 41-60 years, 12.1% (7.6-16.5); 61-80 years, 12.7% (8-17.5); and 81+ years, 13.4% (7.9-18.9). Sex did not affect age-specific prevalence and there was no difference in prevalence between men and women in any age group. In the regression model, the OR of prevalence increasing by age group was 1.06 (0.92-1.2, P = .37). Conclusion This meta-analysis shows the prevalence of subclinical PTC is stable across the lifespan. There is not a higher subclinical PTC prevalence in middle age, in contrast to higher observed incidence rates in this age group. These findings offer unique insights into the prevalence of subclinical PTC and its relationship to age.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据